Melatonin review found fewer delirium cases, with other outcomes uncertain
Pooled intensive-care trials favored melatonin for delirium occurrence, while duration, time in intensive care and mortality showed no statistically significant benefits.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
The pooled evidence favored melatonin for reducing delirium occurrence in critically ill adults. It did not show statistically significant benefits for delirium duration, time in intensive care or survival. These results concern a specific hospital population and do not establish benefits for everyday sleep or supplement use.
The abstract omits doses, follow-up periods and separate ramelteon results. Differences between trials and uncertainty around other outcomes limit interpretation.
What researchers found
Delirium incidence
Melatonin versus controls in adult intensive-care trials; follow-up unspecified. Delirium risk was estimated at 0.75 times control risk. The confidence interval gives an uncertainty range entirely favoring lower relative risk. Missing control event risks prevent calculation of an absolute benefit.
Which treatments contributed
Eligible trials tested melatonin or ramelteon against placebo or standard care. The abstract describes the pooled finding as melatonin administration, without clarifying how much each treatment contributed to that result.
Occurrence and duration differ
Fewer people developing delirium does not necessarily mean shorter episodes among those affected. The nonsignificant findings for duration, intensive-care stay and mortality leave room for benefit or harm.
The original publication
Melatonin supplementation reduces delirium incidence in critically ill patients: a systematic review and meta-analysis.
Wu X, Hu P, Wu H et al.
Front Pharmacol · 2026
- PubMed ID
- 41602948
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.